4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $42.56.
A number of brokerages recently commented on FDMT. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, September 23rd. Morgan Stanley assumed coverage on shares of 4D Molecular Therapeutics in a report on Thursday, November 21st. They issued an "underweight" rating and a $8.00 price objective on the stock. Leerink Partners reissued an "outperform" rating and set a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Chardan Capital reiterated a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th.
Check Out Our Latest Stock Analysis on FDMT
Institutional Trading of 4D Molecular Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in 4D Molecular Therapeutics by 9.6% during the second quarter. Principal Financial Group Inc. now owns 21,034 shares of the company's stock worth $442,000 after acquiring an additional 1,849 shares during the period. Algert Global LLC boosted its position in shares of 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Algert Global LLC now owns 16,588 shares of the company's stock valued at $348,000 after purchasing an additional 2,828 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $40,000. The Manufacturers Life Insurance Company raised its holdings in shares of 4D Molecular Therapeutics by 25.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company's stock worth $398,000 after purchasing an additional 3,850 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after purchasing an additional 3,922 shares during the last quarter. Institutional investors own 99.27% of the company's stock.
4D Molecular Therapeutics Trading Up 5.1 %
NASDAQ FDMT traded up $0.27 during trading hours on Wednesday, reaching $5.57. The company's stock had a trading volume of 1,631,476 shares, compared to its average volume of 906,642. The business has a 50-day simple moving average of $7.38 and a 200 day simple moving average of $12.94. 4D Molecular Therapeutics has a 52 week low of $5.22 and a 52 week high of $36.25. The stock has a market cap of $257.49 million, a PE ratio of -1.95 and a beta of 2.74.
4D Molecular Therapeutics Company Profile
(
Get Free Report4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Recommended Stories
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.